cbdMD regains NYSE American listing compliance and removes .BC flag

cbdMD, Inc. reported that it has regained full compliance with the continued listing standards of the NYSE American exchange.

Rhea-AI Filing Summary

cbdMD, Inc. reported that it has regained full compliance with the continued listing standards of the NYSE American exchange. NYSE Regulation sent the company a letter on December 5, 2025 confirming that previously identified deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide have been resolved. As a result, the “.BC” below-compliance indicator will be removed from cbdMD’s ticker and the company will be taken off the exchange’s list of noncompliant issuers, while remaining subject to normal ongoing listing monitoring.

Positive

• Regained NYSE American compliance, resolving prior deficiencies under Sections 1003(a)(i) and (ii) and removing the “.BC” below-compliance indicator from the company’s listing.

Negative

• None.

Insights

Equity analyst

cbdMD has removed NYSE American compliance risk, stabilizing its listing status.

cbdMD, Inc. received a letter from NYSE Regulation on December 5, 2025 confirming it is back in compliance with all NYSE American continued listing standards in Part 10 of the Company Guide. This resolves earlier deficiencies cited under Sections 1003(a)(i) and (ii), which had placed the company on the exchange’s noncompliant issuer list.

The removal of the “.BC” below-compliance indicator and restoration to normal listing status reduce the risk associated with potential delisting from NYSE American. The company will now be monitored under the exchange’s standard continued listing procedures, aligning its oversight with compliant peers.

Investors can reference the company’s December 8, 2025 press release (Exhibit 99.1) for additional context around this status change, as it outlines the announcement that compliance has been regained.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did cbdMD, Inc. (YCBD) announce in the latest 8-K?

cbdMD, Inc. reported that NYSE Regulation sent a letter on December 5, 2025 confirming the company has regained compliance with all NYSE American continued listing standards.

Why was cbdMD, Inc. previously out of compliance with NYSE American standards?

The company had been cited for deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide, as referenced in letters dated June 5, 2024 and December 31, 2024.

What happens to cbdMD, Inc.’s NYSE American ticker symbol after regaining compliance?

The NYSE American will remove the “.BC” below-compliance indicator from cbdMD’s ticker, and the company will be taken off the exchange’s list of noncompliant issuers.

Will cbdMD, Inc. still be monitored by NYSE Regulation after regaining compliance?

Yes. The company will remain subject to NYSE Regulation’s normal continued listing monitoring, consistent with other compliant issuers on the exchange.

What is Exhibit 99.1 in cbdMD, Inc.’s 8-K filing?

Exhibit 99.1 is a press release dated December 8, 2025 announcing that cbdMD has regained compliance with NYSE American continued listing standards.

Does the cbdMD, Inc. press release count as filed information under the Exchange Act?

No. The company notes that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities or automatically incorporated into other filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/08/2025 - 04:35 PM Learn about SEC filing dates

false 0001644903 0001644903 2025-12-05 2025-12-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2025

cbdMD, INC.

(Exact name of registrant as specified in its charter)

North Carolina	001-38299	47-3414576
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2101 Westinghouse Blvd., Suite A, Charlotte, NC 28273

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (704) 445-3060

_______________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	YCBD	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On December 8, 2025, cbdMD, Inc. (the “Company”) issued a press release announcing that it had regained compliance with the continued listing standards of the NYSE American LLC (the “Exchange”). A copy of the press release is furnished in Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On December 5, 2025, the Company received a letter from NYSE Regulation confirming that the Company has regained compliance with the Exchange.

The letter stated that the Company is back in compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide. Specifically, the Company resolved the previously identified deficiencies under Sections 1003(a)(i) and (ii) of the Company Guide, as referenced in the Exchange’s letters dated June 5, 2024 and December 31, 2024. As a result, the “below compliance” (“.BC”) indicator will be removed and the Company will be taken off the Exchange’s list of noncompliant issuers on the Exchange’s website. The Company will remain subject to NYSE Regulation’s normal continued listing monitoring going forward.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Exhibit Description
99.1*	Press Release dated December 8, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

*The information contained in this Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	cbdMD, Inc.
Date: December 8, 2025	By:	/s/ T. Ronan Kennedy
		T. Ronan Kennedy, Chief Executive Officer and Chief Financial Officer